Search Within

Anita Kumar

  1. "Molecular Imaging and Therapy Service"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (21)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (51)
  2. Department of Medicine (51)
  3. Hematologic Malignancies, Division of (51)
  4. Lymphoma (51)
  5. Molecular Imaging and Therapy Service (51)
  6. Radiology, Department of (51)

More Groups

People
  1. Heiko Schoder (48)
  2. Andrew Zelenetz (46)
  3. Paul Hamlin (42)
  4. Alison Moskowitz (41)
  5. Ariela Noy (40)
  6. Matthew Matasar (39)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (7)
  4. 2022 (4)
  5. 2021 (8)
  6. 2020 (4)

More Years

Publications
  1. Blood (21)
  2. Hematological Oncology (7)
  3. Journal of Clinical Oncology (5)
  4. Haematologica (3)
  5. Blood Cancer Journal (2)
  6. Cancers (2)

More Publications

Publishers
  1. American Society of Hematology (22)
  2. Wiley Blackwell (7)
  3. American Society of Clinical Oncology (5)
  4. Ferrata Storti Foundation (3)
  5. MDPI (2)
  6. Nature Publishing Group (2)

More Publishers

Results (51)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Phase I/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma
    Meeting Abstract

    Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Renal masses detected on FDG PET/CT in patients with lymphoma: Imaging features differentiating primary renal cell carcinomas from renal lymphomatous involvement
    Journal Article

    Nicolau, C.; Sala, E.; Kumar, A.; Goldman, D. A.; Schoder, H.; Hricak, H.; Vargas, H. A.
    American Journal of Roentgenology (2017)

    Fulltext@MSK | Save
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Imaging for staging and response assessment in lymphoma
    Journal Article

    Johnson, S. A.; Kumar, A.; Matasar, M. J.; Schöder, H.; Rademaker, J.
    Radiology (2015)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save